In the BioHarmony Drug Report Database

"Preview" Icon

Lisocabtagene maraleucel

Breyanzi (lisocabtagene maraleucel) is a gene pharmaceutical. Lisocabtagene maraleucel was first approved as Breyanzi on 2021-02-05. It is used to treat b-cell lymphoma in the USA.

 

Trade Name

 

Breyanzi
 

Common Name

 

lisocabtagene maraleucel
 

ChEMBL ID

 

CHEMBL4297236
 

Indication

 

b-cell lymphoma
 

Drug Class

 

Antineoplastic

Image (chem structure or protein)

Lisocabtagene maraleucel structure rendering